Cancers | Free Full-Text | The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?
DNA and amino acid sequences in the transmembrane domain of HER2 . A )... | Download Scientific Diagram
The extracellular domain of Her2 in serum as a biomarker of breast cancer | Laboratory Investigation
Addgene: HER2 WT Sequences
Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer
Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers - The Lancet Oncology
Characterization of N- and C-termini of HER2 protein by mass spectrometry-based sequencing: Observation of two types of N-terminal sequence - ScienceDirect
A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers | Nature Communications
Development of a molecule-recognized promoter DNA sequence for inhibition of HER2 expression | The Journal of Antibiotics
HER2-PI9 and HER2-I12: two novel and functionally active splice variants of the oncogene HER2 in breast cancer | SpringerLink
HER2 - Wikipedia
Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars | SpringerLink
Frontiers | A Novel Small Molecular Antibody, HER2-Nanobody, Inhibits Tumor Proliferation in HER2-Positive Breast Cancer Cells In Vitro and In Vivo
HER2 - Wikipedia
Origins of-helix C conformational flexibility in HER2. A, sequence... | Download Scientific Diagram
Structures of HER2 transcript variants. A) Full-length HER2; NCBI... | Download Scientific Diagram
Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab | Molecular Cancer | Full Text
HER2-positive Metastatic Breast Cancer: Is There a Best Treatment Sequence? (Transcript)
Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies - ScienceDirect
HER2-Driven Carcinogenesis: New Mouse Models for Novel Immunotherapies | IntechOpen
Structural basis for high-affinity HER2 receptor binding by an engineered protein | PNAS
A HER2 bispecific antibody can be efficiently expressed in Escherichia coli with potent cytotoxicity
A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer: Molecular Therapy - Methods & Clinical Development
